Andaloussi-Saghir Khalid, Oukabli Mohamed, El Marjany Mohammed, Sifat Hassan, Hadadi Khalid, Mansouri Hamid
Department of Radiotherapy Oncology, Mohammed V Military Hospital, Rabat, Morocco.
N Am J Med Sci. 2011 Nov;3(11):527-30. doi: 10.4297/najms.2011.3527.
Gliosarcoma is a rare variant of glioblastoma multiforme containing distinct gliomatous and sarcomatous components. Gliosarcoma comprise 1.8-8% of glioblastoma multiforme and are clinically similar to them, affecting adults in the fourth and sixth decades of life, with a higher proportion found in males. The survival for patients with Gliosarcoma is equally poor as for those with glioblastoma multiforme, and there is a greater propensity for extracranial metastasis in Gliosarcoma. Clinical treatment-related experience reported in the literature is limited, and Gliosarcoma are currently treated in a similar fashion to glioblastoma multiforme, with modalities including tumor resection, postoperative radiation therapy, and chemotherapy. Gliosarcoma can arise secondarily, after conventional adjuvant treatment of high-grade glioma. The current literature on the occurrence of secondary gliosarcoma after glioblastoma multiforme is limited, with only 54 reported cases.
The authors present a 48-year-old Caucasian male who had previously received postoperative combined radiation and temozolomide chemotherapy for glioblastoma multiforme. After a free disease period of 9 months the disease recurs as Gliosarcoma. The patient underwent a Total surgical excision and received chemotherapy with a basis of bevacizumab and irinotecan. The patient died from tumor progression 5 months after gliosarcoma diagnosis.
The poor survival of patients with secondary gliosarcoma who had previously received combined radiation and temozolomide chemotherapy for glioblastoma multiforme may reflect a unique molecular profile of glioblastoma multiforme that eventually recurs as secondary gliosarcoma. We have to keep in mind the possibility of gliosarcomatous change in the recurrence of malignant glioma. Awareness of this pathological entity will allow more rapid diagnosis and treatment.
胶质肉瘤是多形性胶质母细胞瘤的一种罕见变体,包含不同的胶质瘤成分和肉瘤成分。胶质肉瘤占多形性胶质母细胞瘤的1.8 - 8%,临床症状与后者相似,主要影响40至60岁的成年人,男性患者比例更高。胶质肉瘤患者的生存率与多形性胶质母细胞瘤患者同样较差,且胶质肉瘤更易发生颅外转移。文献报道的临床治疗相关经验有限,目前胶质肉瘤的治疗方式与多形性胶质母细胞瘤相似,包括肿瘤切除、术后放疗和化疗。胶质肉瘤可在高级别胶质瘤的常规辅助治疗后继发。目前关于多形性胶质母细胞瘤继发胶质肉瘤的文献有限,仅有54例报道病例。
作者介绍了一名48岁的白种男性,他之前因多形性胶质母细胞瘤接受了术后联合放疗和替莫唑胺化疗。在9个月的无病期后,疾病复发为胶质肉瘤。患者接受了根治性手术切除,并接受了以贝伐单抗和伊立替康为基础的化疗。胶质肉瘤诊断5个月后,患者因肿瘤进展死亡。
先前因多形性胶质母细胞瘤接受联合放疗和替莫唑胺化疗的继发胶质肉瘤患者生存率较差,这可能反映了多形性胶质母细胞瘤独特的分子特征,最终复发为继发胶质肉瘤。我们必须牢记恶性胶质瘤复发时发生胶质肉瘤变的可能性。认识到这种病理实体将有助于更快速的诊断和治疗。